A number of potent broadly neutralizing antibodies against HIV-1 have recently been identified that target epitopes on the viral envelope that contain N-linked glycans. It remains unknown how frequently glycan-dependent neutralizing antibodies generally arise during the course of natural infection or whether particular glycosylation sites are preferentially targeted. We tested sera with a broad range of neutralization activity from individuals infected with HIV-1 clades B or C against panels of HIV-1 Env pseudoviruses that lacked specific glycans in the outer domain glycan cluster (ODGC) or inner domain glycan cluster (IDGC) to determine the presence of glycan-dependent neutralizing antibodies. Overall, 54% of individuals were observed to have neutralizing antibodies targeting these glycan regions. Glycan-specific neutralizing antibodies were readily detected in sera that were selected for having broad, moderate, or weak neutralization potency and breadth. Our results demonstrate that glycan-specific neutralizing antibodies arise with appreciable frequency in individuals chronically infected with HIV-1 clades B and C. Antibody responses that commonly occur during natural infection may be more feasible to induce by vaccination; thus glycan-specific neutralizing antibodies may be desirable responses to elicit with candidate HIV-1 vaccines.
Get full access to this article
View all access options for this article.
References
1.
KwongPD and MascolaJR: Human antibodies that neutralize HIV-1: Identification, structures, and B cell ontogenies. Immunity, 2012; 37(3):412–425.
2.
WyattR and SodroskiJ: The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science, 1998; 280(5371):1884–1888.
3.
HuangX, BarchiJJJr, LungFD, et al.: Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-1IIIB GP120 peptide RP135. Biochemistry, 1997; 36(36):10846–10856.
4.
MyersG and LenrootR: HIV glycosylation: What does it portend?. AIDS Res Hum Retroviruses, 1992; 8(8):1459–1460.
5.
WeiX, DeckerJM, WangS, et al.: Antibody neutralization and escape by HIV-1. Nature, 2003; 422(6929):307–312.
6.
MoorePL, GrayES, WibmerCK, et al.: Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med, 2012; 18(11):1688–1692.
7.
WibmerCK, BhimanJN, GrayES, et al.: Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog, 2013; 9(10):e1003738.
8.
BonsignoriM, HwangKK, ChenX, et al.: Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol, 2011; 85(19):9998–10009.
9.
WalkerLM, HuberM, DooresKJ, et al.: Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature, 2011; 477(7365):466–470.
10.
WalkerLM, PhogatSK, Chan-HuiPY, et al.: Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science, 2009; 326(5950):285–289.
11.
McLellanJS, PanceraM, CarricoC, et al.: Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature, 2011; 480(7377):336–343.
12.
MouquetH, ScharfL, EulerZ, et al.: Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci USA, 2012; 109(47):E3268–3277.
13.
PanceraM, YangY, LouderMK, et al.: N332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: Inferences from heavy-light chain complementation of function. PLoS One, 2013; 8(2):e55701.
14.
ScanlanCN, PantophletR, WormaldMR, et al.: The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1→2 mannose residues on the outer face of gp120. J Virol, 2002; 76(14):7306–7321.
15.
BlattnerC, LeeJH, SliepenK, et al.: Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity, 2014; 40(5):669–680.
16.
DerkingR, OzorowskiG, SliepenK, et al.: Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. PLoS Pathog, 2015; 11(3):e1004767.
17.
FalkowskaE, LeKM, RamosA, et al.: Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity, 2014; 40(5):657–668.
18.
HuangJ, KangBH, PanceraM, et al.: Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature, 2014; 515(7525):138–142.
19.
HuangJ, OfekG, LaubL, et al.: Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature, 2012; 491(7424):406–412.
20.
ScheidJF, MouquetH, FeldhahnN, et al.: Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature, 2009; 458(7238):636–640.
21.
ScheidJF, MouquetH, UeberheideB, et al.: Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science, 2011; 333(6049):1633–1637.
22.
WalkerLM, SimekMD, PriddyF, et al.: A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog, 2010; 6(8):e1001028.
23.
WestAPJr, ScharfL, ScheidJF, et al.: Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell, 2014; 156(4):633–648.
24.
SokD, DooresKJ, BrineyB, et al.: Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med, 2014; 6(236):236ra263.
25.
PejchalR, DooresKJ, WalkerLM, et al.: A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science, 2011; 334(6059):1097–1103.
26.
ScharfL, ScheidJF, LeeJH, et al.: Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep, 2014; 7(3):785–795.
27.
Balla-JhagjhoorsinghSS, CortiD, HeyndrickxL, et al.: The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody. PLoS One, 2013; 8(7):e68863.
28.
LavineCL, LaoS, MontefioriDC, et al.: High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection. J Virol, 2012; 86(4):2153–2164.
29.
TomarasGD, BinleyJM, GrayES, et al.: Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol, 2011; 85(21):11502–11519.
30.
BinleyJM, LybargerEA, CrooksET, et al.: Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol, 2008; 82(23):11651–11668.
31.
deCampA, HraberP, BailerRT, et al.: Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol, 2014; 88(5):2489–2507.
32.
HraberP, KorberBT, LapedesAS, et al.: Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. J Virol, 2014; 88(21):12623–12643.
33.
LiM, GaoF, MascolaJR, et al.: Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol, 2005; 79(16):10108–10125.
34.
ChenJ, FreyG, PengH, et al.: Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J Virol, 2014; 88(2):1249–1258.
35.
KorberBFB, KuikenCL, PillaiSK, and SodroskiJ: Numbering positions in HIV relative to HXB2. In: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences (KorberB KC, FoleyB, HahnB, et al., eds.). Los Alamos, NM, Los Alamos National Laboratory, 1998, pp. 102–111.
36.
MontefioriDC: Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol, 2005;Chapter 12:Unit 12 11.
37.
Sarzotti-KelsoeM, BailerRT, TurkE, et al.: Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods, 2014; 409:131–146.
38.
LiM, Salazar-GonzalezJF, DerdeynCA, et al.: Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol, 2006; 80(23):11776–11790.
39.
ZhangM, GaschenB, BlayW, et al.: Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology, 2004; 14(12):1229–1246.
40.
ChuangGY, AcharyaP, SchmidtSD, et al.: Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. J Virol, 2013; 87(18):10047–10058.
41.
WestAPJr, ScharfL, HorwitzJ, et al.: Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proc Natl Acad Sci USA, 2013; 110(26):10598–10603.
42.
TraversSA: Conservation, compensation, and evolution of N-linked glycans in the HIV-1 group M subtypes and circulating recombinant forms. AIDS, 2012; 2012:823605.
43.
KongL, LeeJH, DooresKJ, et al.: Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol, 2013; 20(7):796–803.
44.
TrkolaA, PurtscherM, MusterT, et al.: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol, 1996; 70(2):1100–1108.
45.
GrayES, MadigaMC, HermanusT, et al.: The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol, 2011; 85(10):4828–4840.
46.
SongH, ChuY, ZhangH, et al.: Epitope specificity of cross-clade neutralizing sera from Chinese HIV-1-positive individuals. Scand J Immunol, 2013; 78(4):357–370.
47.
DooresKJ, BonomelliC, HarveyDJ, et al.: Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci USA, 2010; 107(31):13800–13805.
48.
RaskaM, TakahashiK, CzernekovaL, et al.: Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J Biol Chem, 2010; 285(27):20860–20869.
49.
KleinF, MouquetH, DosenovicP, et al.: Antibodies in HIV-1 vaccine development and therapy. Science, 2013; 341: 1199–1204.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
